chr17-43104136-C-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_007294.4(BRCA1):c.427G>T(p.Glu143Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000821 in 1,461,442 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000082 ( 0 hom. )
Consequence
BRCA1
NM_007294.4 stop_gained
NM_007294.4 stop_gained
Scores
2
2
3
Clinical Significance
Conservation
PhyloP100: 1.94
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 17-43104136-C-A is Pathogenic according to our data. Variant chr17-43104136-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 37581.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-43104136-C-A is described in Lovd as [Pathogenic]. Variant chr17-43104136-C-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BRCA1 | NM_007294.4 | c.427G>T | p.Glu143Ter | stop_gained | 6/23 | ENST00000357654.9 | NP_009225.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | ENST00000357654.9 | c.427G>T | p.Glu143Ter | stop_gained | 6/23 | 1 | NM_007294.4 | ENSP00000350283 | P4 |
Frequencies
GnomAD3 genomes
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461442Hom.: 0 Cov.: 33 AF XY: 0.00000963 AC XY: 7AN XY: 727026
GnomAD4 exome
AF:
AC:
12
AN:
1461442
Hom.:
Cov.:
33
AF XY:
AC XY:
7
AN XY:
727026
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome
GnomAD4 genome
Cov.:
32
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:26Uncertain:1
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:10
| Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | May 01, 2012 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Mar 02, 2020 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet | May 27, 2024 | PP3; PS3; PP1_Strong; PM3_Supporting - |
| Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Apr 22, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Michigan Medical Genetics Laboratories, University of Michigan | Nov 03, 2014 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | May 29, 2002 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 11, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 08, 2024 | This variant changes 1 nucleotide in exon 6 of the BRCA1 gene, creating a premature translation stop signal. This variant is expected to result in an absent protein product and BRCA1 mRNA levels is severely reduced in carrier RNA (PMID: 12393792). A functional study has reported that this variant impacts BRCA1 in ubiquitin E3 ligase assays (PMID: 25823446). This variant has been reported in at least 20 individuals and families affected with breast and ovarian cancer (PMID: 9333265, 12393792, 20104584, 23961350, 23884708, 24504028, 26681312, 26833046, 33471991; Leiden Open Variation Database DB-ID BRCA1_000082; Color internal data) and it is a suspected founder mutation in the Irish population (PMID: 23199084). This variant has been identified in 94 families among the CIMBA participants (PMID: 29446198) (https://cimba.ccge.medschl.cam.ac.uk/). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
not provided Pathogenic:8Uncertain:1
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 17, 2021 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in several individuals and families with breast and/or ovarian cancer, and has been reported to be an Irish pathogenic founder variant (van Orsuow 1999, Meyer 2003, van der Hout 2006, Janavicius 2010, Solano 2012, Cunningham 2014, Walsh 2015); Not observed in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 546G>T; This variant is associated with the following publications: (PMID: 32719484, 32338768, 9333265, 29961768, 25525159, 30093976, 29446198, 29506128, 25503966, 18680205, 29422015, 28873162, 25085752, 26733283, 27836010, 28127413, 25673166, 26681312, 25823446, 12938098, 23961350, 20104584, 16683254, 23199084, 24504028, 10528853, 22009639) - |
| Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Oct 13, 2020 | This nonsense variant causes the premature termination of BRCA1 protein synthesis. In addition, it has been reported in individuals affected with breast cancer and ovarian cancer in the published literature (PMID: 27836010 (2016), 24504028 (2014), 23961350 (2012), 22009639 (2012), 20104584 (2010)). This variant has not been reported in large, multi-ethnic general populations. Based on the available information, this variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 20, 2022 | PP5, PM2, PS3, PVS1 - |
| Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 10, 2020 | DNA sequence analysis of the BRCA1 gene demonstrated a sequence change, c.427G>T, which results in the creation of a premature stop codon at amino acid position 143, p.Glu143*. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated BRCA1 protein with potentially abnormal function. This pathogenic sequence change, also reported as c.546G>T in the literature, has previously been described in individuals with breast and/or ovarian cancer, and pancreatic cancer (PMIDs: 9333265, 22009639, 24504028, 20104584, 23961350, 29961768). The p.Glu143* change has not been described in population databases (gnomAD, ExAC). These collective evidences suggest that this sequence change is pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2022 | BRCA1: PVS1, PM2, PS4:Supporting - |
| Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 19, 2017 | The BRCA1 c.427G>T, p.Glu143Ter variant (rs80356991) has been reported in patients with breast or ovarian cancer (Shattuck-Eidens 1997, Cunningham 2014), and listed as pathogenic on ClinVar (Variation ID: 37581). The predicted truncated BRCA1 protein lacks homologous recombination activity when expressed in yeast (Caligo 2009). The variant is not been observed in the general population databases, such as the 1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database. The variant introduces a premature termination codon, and is predicted to result in a truncated protein or an absent transcript. Based on the above information, the p.Glu143Ter variant is classified as pathogenic. References: Caligo M et al. (2009) Hum Mutat. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. 30(1):123-33. Cunningham J et al (2014). Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep. 4:4026. Shattuck-Eidens D et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 278(15):1242-50. - |
Hereditary breast ovarian cancer syndrome Pathogenic:4
| Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 14, 2019 | The p.Glu143X variant in BRCA1 has been reported in >15 individuals with BRCA1-related cancers (Shattuck-Eidens 1997, Caligo 2009, Cunningham 2014, Susswein 2016, Lowery 2018, Yurgelun 2019, BIC database). It was absent from large population studies. This frameshift variant leads to a premature termination codon at position 143, which is predicted to lead to a truncated or absent protein. Loss of function of the BRCA1 gene is an established disease mechanism in autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC). Additionally, this variant was classified as Pathogenic on Apr 22, 2016 by the ClinGen-approved ENIGMA expert panel (Variation ID: 37581). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PVS1, PM2, PS4. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change creates a premature translational stop signal (p.Glu143*) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 9333265, 20104584, 22009639, 23961350, 24504028). This variant is also known as 546G>T and E143X. ClinVar contains an entry for this variant (Variation ID: 37581). For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 31, 2020 | Variant summary: BRCA1 c.427G>T (p.Glu143X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251024 control chromosomes. c.427G>T has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (example, Solano_2013, Judkins_2005, Evans_2003, Nielsen_2016). These data indicate that the variant is very likely to be associated with disease. Nine clinical diagnostic laboratories and one expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:3
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 12, 2021 | The p.E143* pathogenic mutation (also known as c.427G>T), located in coding exon 5 of the BRCA1 gene, results from a G to T substitution at nucleotide position 427. This changes the amino acid from a glutamic acid to a stop codon within coding exon 5. This mutation has been reported in several individuals diagnosed with breast and/or ovarian cancer (Perrin-Vidoz L et al. Hum. Mol. Genet. 2002 Nov;11:2805-14; Borg A et al. Hum. Mutat. 2010 Mar;31:E1200-40; Bayraktar S et al. Cancer. 2012 Mar;118:1515-22; Cunningham JM et al. Sci. Rep. 2014 Feb;4:4026; Susswein LR et al. Genet. Med. 2016 Aug;18:823-32). This alteration has been reported to co-occur with the BRCA2 c.8730delT mutation in a Caucasian patient from Denmark (Rebbeck TR et al. Breast Cancer Res. 2016 Nov;18:112). This alteration has also been reported as a possible Irish founder mutation, after the author noted that it accounted for 22% of all HBOC individuals in an Irish population (Janaviius R. EPMA J. 2010 Sep;1:397-412). It has since been reported in multiple individuals from Western Ireland (McVeigh TP et al. Ir. J. Med. Sci. 2014 Jun;183:199-206). Of note, this alteration is also designated as 546G>T in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
| Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | May 11, 2021 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 17, 2024 | This variant changes 1 nucleotide in exon 6 of the BRCA1 gene, creating a premature translation stop signal. This variant is expected to result in an absent protein product and BRCA1 mRNA levels is severely reduced in carrier RNA (PMID: 12393792). A functional study has reported that this variant impacts BRCA1 in ubiquitin E3 ligase assays (PMID: 25823446). This variant has been reported in at least 20 individuals and families affected with breast and ovarian cancer (PMID: 9333265, 12393792, 20104584, 23961350, 23884708, 24504028, 26681312, 26833046, 33471991; Leiden Open Variation Database DB-ID BRCA1_000082; Color internal data) and it is a suspected founder mutation in the Irish population (PMID: 23199084). This variant has been identified in 94 families among the CIMBA participants (PMID: 29446198; https://cimba.ccge.medschl.cam.ac.uk/). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Familial cancer of breast Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 23, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
D
MutationTaster
Benign
A;A;A;A;A;A;A;A;A;A;N;N;N;N
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at